study	name	time	time_end	time_unit	route	application	measurement_type	form	substance	value	unit	comments
Hornecker2012	SOF400	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	400	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
Hornecker2012	SOF800	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	800	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
Hornecker2012	SOF1200	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	1200	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
Hornecker2012	SOF1600	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	1600	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
Hornecker2012	SOF2000	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	2000	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
Hornecker2012	SOF2400	S-14T1R14	NA	day	oral	multiple dose	dosing	NR	sorafenib	2400	mg	Eligible patients (>18 years old) were treated by single agent sorafenib for at least 2 weeks; unclear if twice daily
